Atrandi Biosciences: Funding, Investors & Team (Sep 2026)
Atrandi Biosciences is a privately owned biotechnology company that specializes in advanced single-cell technology, with a focus on eukaryotic DNA sequencing at the single-cell level. This unique method enables the examination of genetic changes and variations in individual cells.
Atrandi Biosciences has raised $29.8M across 2 funding rounds on record, the most recent a Series A of $25.0M announced in Feb 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Atrandi Biosciences Company Profile and Key Stats
Latest funding round on record: Feb 2025.
Atrandi Biosciences Funding Rounds
Atrandi Biosciences raised $4.8M in a Series A announced in Mar 2023.
1.9 years later, a Series A of $25.0M was announced in Feb 2025.
Atrandi Biosciences Founders and Leadership Team
Contact details for the Atrandi Biosciences team: 1 of 1 has an email address on file.
Start 14-day free trial →Atrandi Biosciences Funding Compared to Other Biotechnology Startups
Atrandi Biosciences' latest round of $25.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Atrandi Biosciences in Biotechnology and Vilnius
Companies Similar to Atrandi Biosciences
Biomatter is a company specializing in synthetic biology that creates new proteins for medical and…
Biohifas employs the power of mycelium and valorizes industrial side streams into the food. We are developing…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
Computomics applies AI to bioinformatics data to enable rapid understanding of genomics and drive advanced…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
Atrandi Biosciences Funding FAQs
What does Atrandi Biosciences do?
Atrandi Biosciences is a privately owned biotechnology company that specializes in advanced single-cell technology, with a focus on eukaryotic DNA sequencing at the single-cell level. This unique method enables the examination of genetic changes and variations in individual cells.
How much funding has Atrandi Biosciences raised?
Atrandi Biosciences has raised $29.8M across 2 rounds on record. The most recent is a Series A of $25.0M announced in Feb 2025.
When did Atrandi Biosciences last raise funding?
Atrandi Biosciences' most recent funding round on record is a Series A of $25.0M, announced in Feb 2025.
Who founded Atrandi Biosciences?
FundedIQ lists Juozas Nainys (Founder) at Atrandi Biosciences.
Where is Atrandi Biosciences headquartered?
Atrandi Biosciences is based in Vilnius, Vilniaus Apskritis, Lithuania.
How many employees does Atrandi Biosciences have?
Atrandi Biosciences is in the 101-250 employee band.
How does Atrandi Biosciences' funding compare to other Biotechnology startups?
Atrandi Biosciences' latest round of $25.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Atrandi Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Atrandi Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.